Chemokine receptor antagonists: A new era of HIV therapy?

被引：3

作者：

Julg, B ^{[1
]}

Goebel, FD ^{[1
]}

机构：

[1] Univ Munich, Dept Infect Dis, Med Poliklin, D-80336 Munich, Germany

来源：

INFECTION | 2005年 / 33卷 / 5-6期

关键词：

D O I：

10.1007/s15010-005-6605-8

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Chemokine receptors are essential for human immunodeficiency virus (HIV) cell entry. CXCR4 and CCR5 are the two most relevant receptors and by inhibition of each of them a delayed onset of disease could be achieved. As both receptors are used at different stages of disease due to the domination of different HIV strains, a dual blockage of CXCR4 and CCR5 could be highly valuable for inhibiting viral transmission and replication.

引用

页码：408 / 410

页数：3

共 23 条

[1] Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects
Adkison, KK
Shachoy-Clark, A
Fang, L
Lou, Y
O'Mara, K
Berrey, MM
Piscitelli, SC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) : 2802 - 2806
[2] CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1
Alkhatib, G
Combadiere, C
Broder, CC
Feng, Y
Kennedy, PE
Murphy, PM
Berger, EA
[J]. SCIENCE, 1996, 272 (5270) : 1955 - 1958
[3] HIV blocked by chemokine antagonist
ArenzanaSeisdedos, F
Virelizier, JL
Rousset, D
ClarkLewis, I
Loetscher, P
Moser, B
Baggiolini, M
[J]. NATURE, 1996, 383 (6599) : 400 - 400
[4] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M
Nishimura, O
Kanzaki, N
Okamoto, M
Sawada, H
Iizawa, Y
Shiraishi, M
Aramaki, Y
Okonogi, K
Ogawa, Y
Meguro, K
Fujino, M
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) : 5698 - 5703
[5] A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains
Berson, JF
Long, D
Doranz, BJ
Rucker, J
Jirik, FR
Doms, RW
[J]. JOURNAL OF VIROLOGY, 1996, 70 (09) : 6288 - 6295
[6] The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C
Cilliers, T
Nhlapo, J
Coetzer, M
Orlovic, D
Ketas, T
Olson, WC
Moore, JP
Trkola, A
Morris, L
[J]. JOURNAL OF VIROLOGY, 2003, 77 (07) : 4449 - 4456
[7] IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS
COCCHI, F
DEVICO, AL
GARZINODEMO, A
ARYA, SK
GALLO, RC
LUSSO, P
[J]. SCIENCE, 1995, 270 (5243) : 1811 - 1815
[8] Change in coreceptor use correlates with disease progression in HIV-1-infected individuals
Connor, RI
Sheridan, KE
Ceradini, D
Choe, S
Landau, NR
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) : 621 - 628
[9] Identification of a major co-receptor for primary isolates of HIV-1
Deng, HK
Liu, R
Ellmeier, W
Choe, S
Unutmaz, D
Burkhart, M
DiMarzio, P
Marmon, S
Sutton, RE
Hill, CM
Davis, CB
Peiper, SC
Schall, TJ
Littman, DR
Landau, NR
[J]. NATURE, 1996, 381 (6584) : 661 - 666
[10] AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
Donzella, GA
Schols, D
Lin, SW
Esté, JA
Nagashima, KA
Maddon, PJ
Allaway, GP
Sakmar, TP
Henson, G
De Clercq, E
Moore, JP
[J]. NATURE MEDICINE, 1998, 4 (01) : 72 - 77

← 1 2 3 →